MeSH D033461 - hyperuricemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Febuxostat | Febuxostat Mylan | 2017-06-15 | |||
| Sanofi | Rasburicase | Elitek | 2002-07-12 | |||
| Rasburicase | Fasturtec | 2001-02-23 | ||||
| Krka | Febuxostat | Febuxostat Krka | 2019-03-28 | |||
| Ironwood Pharmaceuticals | Lesinurad, Allopurinol | Duzallo | 2025-08-25 | 2017-08-18 | ||
| Lesinurad | Zurampic | 2025-08-25 | 2015-12-22 | $0.8 M | Y2017 | |
| Grünenthal | Lesinurad, Allopurinol | Duzallo | 2018-08-23 | |||
| Lesinurad | Zurampic | 2016-02-18 |
Clinical Trials
Historical Success Rate
Phase 1
43%6/14
Phase 2
47%8/17
Phase 3
92%12/13
Approved: 5Overall Success rate: 19%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use